Research grade

COA available

Research Peptide

Sermorelin 5mg

GHRH(1-29) — shortest fully functional fragment of growth hormone-releasing hormone 29 amino acids · Retains complete GHRH receptor binding activity Research-grade · CAS 86168-78-7 For in vitro GHRH receptor research only

$36.99 In stock

Research-Grade CompoundsManufactured to research-grade standards for laboratory research use only.

Discreet ShippingEvery order ships in plain, protective packaging.

In-House FulfillmentOrders are inspected, packed, and shipped directly by the Heritage Labs team.

Same-day dispatch on orders before 12:00 PM ET, Mon–Fri. Discreet, plain packaging.

In-House Fulfillment Orders are inspected, packed, and shipped directly by the Heritage Labs team.

View this compound’s Certificate of Analysis →

SSL 256-bit Secure Checkout

For laboratory research use only. Not for human or veterinary consumption. SKU SMO5.

Overview

Product details.

Sermorelin 5mg — GHRH(1-29)

In 1985, Clark and Robinson published a finding in Nature that shaped the next four decades of growth hormone research: the first 29 amino acids of GHRH are all you need for full receptor activation. The remaining 15 C-terminal residues are biologically irrelevant (PubMed 2858818). That minimal active fragment is Sermorelin.

Research-Grade Compounds

Manufactured to research-grade standards for laboratory research use only.

Discreet Shipping

Every order ships in plain, protective packaging.

In-House Fulfillment

Orders are inspected, packed, and shipped directly by the Heritage Labs team.

What makes Sermorelin particularly interesting as a research tool is what it does not do. Published studies report that it does not significantly affect prolactin, insulin, cortisol, glucose, or thyroid hormone levels in experimental systems. Changes are confined to the somatotropic axis (Prakash & Goa, BioDrugs, 1999; PubMed 18031173). That specificity makes it a clean tool for studying GH signaling without metabolic confounders.

Specifications

Amino Acids	29
Molecular Formula	C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight	3357.93 g/mol
CAS Number	86168-78-7
PubChem CID	16129620
Form	Lyophilized powder (acetate salt)
Appearance	White to off-white powder
Available Sizes	5mg and 10mg per vial

Mechanism and kinetics

Sermorelin binds GHRH receptors on pituitary somatotrophs, triggering adenylate cyclase activation, cAMP accumulation, PKA phosphorylation, and GH vesicle release. Its circulating half-life is approximately 11-12 minutes — short compared to modified analogs like CJC-1295, but this actually produces a more physiologically representative pulsatile secretion pattern.

There is one property that sets Sermorelin apart from many receptor agonists: chronic exposure upregulates GHRH receptor production rather than causing desensitization (Garcia et al., Endotext/NCBI, 2019). Most receptor systems down-regulate under sustained agonism. This one does not.

Key published findings

Khorram et al. documented GH enhancement of 82% within 2 hours and 107% over 16-week periods, with IGF-1 increases of roughly 28%. Body composition analysis showed a mean lean mass gain of 2.78 lbs (1.26 kg) with measurable changes in skin tissue thickness (J Clin Endocrinol Metab, 1997; PubMed 9141541).

Vitiello et al. examined cognitive outcomes in a cohort of 89 subjects aged 68-69, reporting observations related to WAIS performance metrics including IQ, picture arrangement, and verbal scores (Neurobiology of Aging, 2006; PubMed 16399214).

Sermorelin vs CJC-1295

Both target the GHRH receptor but differ in staying power. Sermorelin is the unmodified 1-29 fragment (~11 min half-life). CJC-1295 No DAC has four amino acid substitutions for DPP-IV resistance (30 min to 2 hours). CJC-1295 with DAC adds albumin binding (6-8 days). The tradeoff is always the same: longer half-life means less pulsatile secretion. All three are available from Heritage Labs USA.

Research applications

GHRH receptor binding kinetics and affinity studies
Somatotroph signaling cascade characterization
Comparative GHRH analog pharmacology (Sermorelin vs CJC-1295 vs Tesamorelin)
Receptor desensitization vs upregulation research
GH pulsatility and secretion pattern analysis

Quality and testing

Every Heritage Labs compound is manufactured to research-grade standards and shipped in protective packaging.

Storage

Lyophilized: -20°C for long-term stability
Reconstituted: 2-8°C, use within 30 days
Protection: Shield from light and moisture; avoid freeze-thaw cycles

References

Clark RG, Robinson ICAF. “Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor.” Nature. 1985;314(6008):281-283. PubMed 2858818
Khorram O, et al. “Two years of treatment with recombinant human growth-hormone releasing hormone.” J Clin Endocrinol Metab. 1997;82(5):1472-1479. PubMed 9141541
Prakash A, Goa KL. “Sermorelin: a review.” BioDrugs. 1999;12(2):139-157. PubMed 18031173
Vitiello MV, et al. “Growth hormone releasing hormone improves the cognition of healthy older adults.” Neurobiol Aging. 2006;27(2):318-323. PubMed 16399214
Garcia JM, et al. “Growth Hormone in Aging.” Endotext/NCBI. 2019.

Frequently paired with

Ipamorelin 5mg — Complementary GHS-R agonist for dual-pathway GH studies.
CJC-1295 No DAC — Extended-duration GHRH analog comparison.

For laboratory research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.

For laboratory research use only. Not for human or veterinary use. This product is not a drug or supplement and is not intended to diagnose, treat, cure, or prevent any disease.

FDA DISCLAIMER: All products are intended for research use only as defined by the FDA. Not for use in diagnostic procedures, human use, or veterinary use. Products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. All products sold by Heritage Labs are intended strictly for laboratory research, analytical, or in-vitro purposes only. Heritage Labs operates as a chemical supplier and is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act. Additionally, Heritage Labs is not classified as an outsourcing facility under Section 503B of the same Act. The statements on this website have not been evaluated by the U.S. Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease.